Form 4: Pfizer CEO Albert Bourla Acquires Phantom Stock Units

Pfizer Chairman and CEO Albert Bourla acquired 22 phantom stock units through the company's deferred compensation plan.

Summary

• Albert Bourla, Chairman and CEO of Pfizer Inc., acquired 22 phantom stock units on April 15, 2026.
• The units were acquired under the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.
• Each unit represents one phantom share of common stock valued at $27.19 per unit.
• Following this transaction, the reporting person holds a total of 760,070 phantom stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding executive compensation and does not indicate a change in company outlook.

Positives

• Continued alignment of executive interests with company performance through deferred compensation participation.

Negatives

• None identified.

Risks

• Value of phantom stock units is subject to the underlying performance of Pfizer common stock.

Future Outlook

The units are settled in cash following the reporting person's separation from service, reflecting long-term retention and compensation planning.

Management Comments

• The acquisition was made pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan.

Industry Context

StockSavvy.ai notes that executive participation in deferred compensation plans is a standard corporate governance practice, signaling long-term commitment to the firm's equity performance.

Comparison to Industry Standards

• The use of phantom stock units for executive compensation is consistent with standard practices at large-cap pharmaceutical companies like Merck, Bristol Myers Squibb, and Eli Lilly.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard internal compensation adjustment.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

Pfizer, PFE, Albert Bourla, Form 4, Insider Trading, Phantom Stock